Scleroderma renal crisis

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 6, 2015, Pages 687-694

  Bose, Nilanjana ^a   Chiesa Vottero, Andres ^a   Chatterjee, Soumya ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Scleroderma; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

COMPLICATION; DISEASE COURSE; HUMAN; HYPERTENSION, MALIGNANT; PATHOPHYSIOLOGY; PROGNOSIS; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SCLERODERMA, SYSTEMIC;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, MALIGNANT; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84921328359     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.12.001     Document Type: Review

References (67)

1. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012, 24:165-170.
2. Domsic R.T., Rodriguez-Reyna T., Lucas M., Fertig N., Medsger T.A. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011, 70:104-109.
3. Steen V.D. Scleroderma renal crisis. Rheum Dis Clin North Am 2003, 29:315-333.
4. Nihtyanova S.I., Tang E.C., Coghlan J.G., Wells A.U., Black C.M., Denton C.P. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010, 103:109-115.
5. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
6. Auspitz H. Ein beitrag zur lehre vom haut-sklerem der erwachsenen. Wien Med Wochenschr 1863, xiii:755.
7. Hochberg M., Silman A., Smolen J., Weinblatt M., Weisman M. Clinical features of systemic sclerosis. Rheumatology 2011, 1373. Elsevier. 5th ed.
8. Masugi M., Ya-shu Die diffuse sklerodermie und ihre gefassveranderung. Virchow S Arch Path Anat U Physiol 1938, 302:39-62.
9. Talbott J.H.G., Consolazio W., Coombs F. Dermatomyositis with scleroderma, calcinosis and renal endarteritis associated with focal cortical necrosis. Arch Int Med 1939, 63:476.
10. Goetz R.H. The pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in viscera. Clin Proc 1945, 4:337.
11. MOORE H.C., SHEEHAN H.L. The kidney of scleroderma. Lancet 1952, 1(6698):68-70.
12. Steen V.D., Mayes M.D., Merkel P.A. Assessment of kidney involvement. Clin Exp Rheumatol 2003, 21(3 Suppl. 29):S29-S31.
13. Hudson M., Baron M., Tatibouet S., Furst D.E., Khanna D. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis: Results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014, 43:666-672.
14. Penn H., Howie A.J., Kingdon E.J., Bunn C.C., Stratton R.J., Black C.M., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007, 100:485-494.
15. Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
16. Traub Y.M., Shapiro A.P., Rodnan G.P., Medsger T.A., McDonald R.H., Steen V.D., et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 1983, 62:335-352.
17. Fisher E.R., Rodnan G.P. Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol 1958, 65:29-39.
18. Cannon P.J., Hassar M., Case D.B., Casarella W.J., Sommers S.C., LeRoy E.C. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974, 53:1-46.
19. Kovalchik M.T., Guggenheim S.J., Silverman M.H., Robertson J.S., Steigerwald J.C. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978, 89:881-887.
20. Clements P.J., Lachenbruch P.A., Furst D.E., Maxwell M., Danovitch G., Paulus H.E. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 1994, 37:67-74.
21. Halevy D., Radhakrishnan J., Markowitz G., Appel G. Thrombotic microangiopathies. Crit Care Clin 2002, 18:309-320. [vi].
22. Batal I., Domsic R.T., Medsger T.A., Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010, 2010:543704.
23. Batal I., Domsic R.T., Shafer A., Medsger T.A., Kiss L.P., Randhawa P., et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009, 40:332-340.
24. Steen V.D., Syzd A., Johnson J.P., Greenberg A., Medsger T.A. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005, 32:649-655.
25. Scheja A., Bartosik I., Wuttge D.M., Hesselstrand R. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009, 38:295-298.
26. Kamen D.L., Wigley F.M., Brown A.N. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma-a different kind of renal crisis. J Rheumatol 2006, 33:1886-1888.
27. Locke I.C., Worrall J.G., Leaker B., Black C.M., Cambridge G. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997, 24:86-89.
28. Steen V.D., Medsger T.A., Osial T.A., Ziegler G.L., Shapiro A.P., Rodnan G.P. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984, 76:779-786.
29. Teixeira L., Mouthon L., Mahr A., Berezne A., Agard C., Mehrenberger M., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008, 67:110-116.
30. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
31. Penn H., Denton C.P. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008, 20:692-696.
32. Trang G., Steele R., Baron M., Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012, 32:645-653.
33. Guillevin L., Berezne A., Seror R., Teixeira L., Pourrat J., Mahr A., et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 2012, 51:460-467.
34. Denton C.P., Sweny P., Abdulla A., Black C.M. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994, 33:90-92.
35. DeMarco P.J., Weisman M.H., Seibold J.R., Furst D.E., Wong W.K., Hurwitz E.L., et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002, 46:2983-2989.
36. Nguyen B., Mayes M.D., Arnett F.C., del J.D., Reveille J.D., Gonzalez E.B., et al. HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011, 63:530-534.
37. Yanaba K., Asano Y., Tada Y., Sugaya M., Kadono T., Hamaguchi Y., et al. Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol 2012, 31:835-839.
38. Maki S., Miyauchi T., Kakinuma Y., Sakai S., Kobayashi T., Sugiyama F., et al. The endothelin receptor antagonist ameliorates the hypertensive phenotypes of transgenic hypertensive mice with renin-angiotensin genes and discloses roles of organ specific activation of endothelin system in transgenic mice. Life Sci 2004, 74:1105-1118.
39. Fonseca C., Renzoni E., Sestini P., Pantelidis P., Lagan A., Bunn C., et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 2006, 54:3034-3042.
40. Kobayashi H., Nishimaki T., Kaise S., Suzuki T., Watanabe K., Kasukawa R., et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999, 18:425-427.
41. Mouthon L., Mehrenberger M., Teixeira L., Fakhouri F., Berezne A., Guillevin L., et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011, 42:95-102.
42. Penn H., Quillinan N., Khan K., Chakravarty K., Ong V.H., Burns A., et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013, 106:839-848.
43. Chighizola C.B., Penn H., Meroni P.L., Denton C.D., Ong V. The N-terminal fragment of brain natriuretic peptide as an outcome predictor in scleroderma renal crisis. Arthritis Rheum 2011, 63:S573.
44. Tormey V.J., Bunn C.C., Denton C.P., Black C.M. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001, 40:1157-1162.
45. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
46. Graf S.W., Hakendorf P., Lester S., Patterson K., Walker J.G., Smith M.D., et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012, 15:102-109.
47. Nihtyanova S.I., Parker J.C., Black C.M., Bunn C.C., Denton C.P. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009, 48:1218-1221.
48. Codullo V., Cavazzana I., Bonino C., Alpini C., Cavagna L., Cozzi F., et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009, 36:1464-1469.
49. Nguyen B., Assassi S., Arnett F.C., Mayes M.D. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010, 37:1068.
50. Steen V.D., Medsger T.A. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000, 133:600-603.
51. Denton C.P., Lapadula G., Mouthon L., Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 2009, 48(Suppl. 3):iii32-iii35.
52. Zhu M.S., Chen J.Z., Xu A.P. Factors that can minimize bleeding complications after renal biopsy. Int Urol Nephrol 2014, 46:1969-1975.
53. Torok K.S., Cortese-Hassett A., Kiss J.E., Lucas M., Medsger T.A. Scleroderma renal crisis and thrombotic thrombocytopenic purpura: are they related?. Arthritis Rheum 2008, 58:S377-S378.
54. Lopez-Ovejero J.A., Saal S.D., D'Angelo W.A., Cheigh J.S., Stenzel K.H., Laragh J.H. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979, 300:1417-1419.
55. Collins D.A., Patel S., Eastwood J.B., Bourke B.E. Favourable outcome of scleroderma renal crisis. J R Soc Med 1996, 89:49P-50P.
56. Walker J.G., Ahern M.J., Smith M.D., Coleman M., Pile K., Rischmueller M., et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 2003, 33:216-220.
57. Cheung W.Y., Gibson I.W., Rush D., Jeffery J., Karpinski M. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 2005, 45:930-934.
58. Dhaun N., MacIntyre I.M., Bellamy C.O., Kluth D.C. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis 2009, 54:726-731.
59. Josselin-Mahr L., Carbonne B., Cabane J. Systemic sclerosis and pregnancy. Rev Med Interne 2011, 32:363-368.
60. Abbott K.C., Trespalacios F.C., Welch P.G., Agodoa L.Y. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002, 15:236-240.
61. Richardson J.A. Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum 1973, 16:265-271.
62. Chang Y.J., Spiera H. Renal transplantation in scleroderma. Medicine 1999, 78:382-385.
63. Gibney E.M., Parikh C.R., Jani A., Fischer M.J., Collier D., Wiseman A.C. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004, 4:2027-2031.
64. Woodhall P.B., McCoy R.C., Gunnells J.C., Seigler H.F. Apparent recurrence of progressive systemic sclerosis in a renal allograft. J Am Med Assoc 1976, 236:1032-1034.
65. Pham P.T., Pham P.C., Danovitch G.M., Gritsch H.A., Singer J., Wallace W.D., et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005, 5:2565-2569.
66. Gliddon A.E., Dore C.J., Black C.M., McHugh N., Moots R., Denton C.P., et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007, 56:3837-3846.
67. Steen V.D., Costantino J.P., Shapiro A.P., Medsger T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113:352-357.